Omaglo 25 mg is a Product of the Generic Omarigliptin

What Is Omaglo 25 mg Indications and Uses?

Omarigliptin is indicated for the treatment of adults with type 2 diabetes.

Pharmacology (Source, Chemical and Physical Composition) Of Omaglo 25 mg

Omarigliptin is a long-acting inhibitor of the enzyme dipeptidyl peptidase-4 (DPP- 4). DPP-4 rapidly degrades incretin hormones. Incretins lower blood glucose concentrations in response to a meal by increasing insulin and decreasing glucagon levels in a glucose-dependent manner. Thus, Omarigliptin's mechanism of action augments the action of incretin hormones.

Dosage And Administration of Omaglo 25 mg

Route of administration: Omarigliptin tablets should be taken in oral route.Recommended dosage: The recommended dose of Omarigliptin is 25 mg once weekly as monotherapy or as add-on therapy for optimisation of glycemic control. If patient misses a dose, advice to take the missed dose as soon as possible and then follow the regular weekly dosing schedule. Never take two doses at one time. Renal impairment: The dosage in patients with severe renal dysfunction or with end-stage renal failure or in those requiring hemodialysis or peritoneal dialysis should be according to the following: Severe end-stage kidney failur-

Men: CrCl>1.9: 12.5 mg once a week
Women: CrCl >1.4: 12.5 mg once a week.

Use in children and adolescents: Safety and efficacy of omarigliptin in children and adolescents have not been established.

Drug Interactions of Omaglo 25 mg

Drug interaction with medication: Omarigliptin interacts with metformin, glimepiride, oral contraceptives and atorvastatin. Other anti-diabetic drugs (in particular, insulin preparation or sulfonylurea) should be used with caution in combination with omarigliptin, as they may cause hypoglycemia. Precaution must be taken with drugs that enhances the hypoglycemic action (3-blockers, salicylic acid agents, monoamine oxidase inhibitors). Blood glucose level should be carefully monitored when using drugs that attenuate the hypoglycemic action (adrenaline, adrenocorticotropic hormone, thyroid hormone).

Side Effects of Omaglo 25 mg

The adverse effects of omarigliptin are generally well tolerated. The most common side effects are nasopharyngitis, hypoglycemia, constipation, diarrhea, gastrointestinal problem, skin and subcutaneous tissue disorders.

Use During Pregnancy and Lactation

Clinical trials on use of omarigliptin in pregnant women have not been performed. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Breastfeeding should be avoided in mothers taking omarigliptin.

Precautions And Warnings for Omaglo 25 mg

Omarigliptin should be administered with caution in following patients or conditions which might cause low blood sugar such as pituitary dysfunction or adrenal insufficiency; malnutrition, starvation, irregular dietary intake, lack of dietary intake or debilitated state; intense muscle movement; excessive alcohol intake and elder person. Caution should be taken in patients engaged in aerial work or operation of an automobile.

Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Storage Conditions of It

Store in a cool (below 30°C) & dry place protected from the light. Keep away from the reach of children.